Swedish Heart Institute Becomes One of First Programs in Country to Begin Offering Newly Approved Dr

Swedish Heart Institute Becomes One of First Programs in Country to Begin Offering Newly Approved Drug-Eluting Stent

SEATTLE, March 24, 2003 -- Swedish Medical Center's Heart Institute now offers the new CYPHER Sirolimus-eluting Stent, the first drug-eluting stent to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of blocked coronary arteries.


The new CYPHER Stent, which is approved for the treatment of previously untreated coronary artery lesions, was developed to address the problem of in-stent restenosis, or reblockage, which occurs in as many as 15 percent to 30 percent of patients who receive a bare-metal stent. The stent is coated with the drug sirolimus, which is slowly released into the vessel lining to prevent scar tissue growth through the openings in the stent mesh that frequently leads to restenosis.

"The CYPHER Stent provides new hope for patients with challenging case histories," said Mark Reisman, M.D., director of the Swedish Heart Institute's Cardiovascular Research program. "We are pleased to provide this advanced stent therapy in our community and be one of the first hospitals in the United States to offer this effective treatment to patients."

Results of large-scale studies involving nearly 1,400 patients worldwide show that the CYPHER Stent, manufactured by Cordis Corporation, a Johnson & Johnson company, reduces the incidence of restenosis by more than 90 percent over a bare-metal stent.

More than 1,000 stenting procedures are performed annually at Swedish by an experienced team of interventional cardiologists. The availability of this new drug-eluting stent is expected to generate widespread interest.

"The Swedish Heart Institute is committed to bringing patients innovative new technologies that have a positive effect on end results. We provide many options to our patients and encourage those who have questions about the CYPHER Stent to speak to their cardiologist," said Dr. Reisman.

For more information about the new drug-eluting stent, visit www.cordis.com.

# # #

Swedish Medical Center is the largest, most comprehensive, not-for-profit health provider in the Pacific Northwest. It is comprised of three hospital campuses (First Hill, Ballard and Providence), Swedish Home Care Services and Swedish Physicians -- a network of 11 primary-care clinics. In addition to general medical and surgical care, Swedish is known as a regional referral center, providing specialized treatment in areas such as cardiac care (Swedish Heart Institute), oncology, orthopedics, high-risk obstetrics, neurological care, sleep medicine, pediatrics, organ transplantation and clinical research. For more information, visit www.swedish.org.

Media coverage

  • To read the transcript of a story KOMO Television (Seattle's ABC affiliate; channel 4) ran about this, click here.
  • For more information about the latest research about drug-coated stents published in the New England Journal of Medicine, click here.
Blog post currently doesn't have any comments.
Leave comment

 Security code